Navigation Links
Old drug, new tricks: Prospects for slashing the impact of malaria

A dramatic reduction in the impact of malaria is in prospect with a clinical drug trial to begin in Papua New Guinea early next year. Success in the trial would open the way to relief in the 10% of humanity infected with this debilitating and often fatal disease - over 500,000,000 people.

The Walter and Eliza Hall Institute of Medical Research is collaborating with the Papua New Guinea Institute of Medical Research (PNGIMR) and the University of Melbourne to confirm significant health benefits in the new application of an old malaria drug - at just 12 cents a dose. The project is supported by a AUD$3. 7 million grant to PNGIMR from the Bill and Melinda Gates Foundation.

Fansidar is a 20-year-old malaria drug. As with many other such curative drugs, its effectiveness has declined over time with increased resistance by the malaria parasite. But initial clinical evidence suggests that Fansidar could have a new lease on life as a protective drug that strengthens a person's own immune system against malaria.

Early field experiments were conducted in the African country of Tanzania in the late 1990s. These suggested that giving just one Fansidar tablet to an apparently healthy child during their routine infant immunization visits dramatically reduced the impact of any subsequent malaria infection. Used in this way, Fansidar does not prevent malaria but seems to produce a massive 50% reduction in death, debilitation and complications of malaria, such as severe anaemia and raging fevers.

Joint project leader, Dr Louis Schofield from WEHI, says, "There seems to be a totally unexpected residual immunological effect when children are given this tablet as a preventative rather than as a post-infection treatment for malaria. While the drug itself dissipates in the bloodstream over a few days, it appears to enable the immune system to re-energize and more successfully combat any subsequent malarial infection. We suspect that many toddlers who se em reasonably healthy might actually have low level malarial infections that are eliminated by Fansidar, allowing the immune system to develop to its full potential."

WEHI's Dr James Beeson adds, "Most of the 2 million or so annual deaths from malaria and much of the severe illness involves children under five years of age. Pregnant women are also highly susceptible to the effects of malaria, but the good news is that they too appear to have much greater immune protection conferred by the preventative or 'presumptive' use of Fansidar. This looks like a case of teaching an old drug new tricks - or perhaps the old drug teaching us that it can perform tricks that we never suspected it could."

The four-year trial is being conducted in PNG for a number of reasons. First, PNG is a relatively confined area with a high concentration of all four types of global malaria ?unlike Africa, where one type predominates. Second, outstanding field researchers with clinical trial capability from the PNGIMR can collaborate with world leading Australian experts in malaria from WEHI and the University of Melbourne. Third, the organizational and public health infrastructure already exists to dispense the tablets in a controlled way, since PNG's children routinely attend clinics to be vaccinated against a range of other diseases.

The project funding allows significant expansion of joint activities and research among the collaborating institutions.

Successful completion of the trial is likely to help inform global health policy in combating this most serious disease of humanity.


'"/>

Source:Research Australia


Related biology news :

1. Researchers reveal the infectious impact of salmon farms on wild salmon
2. Measuring the impact of post-genomics on Mediterranean populations
3. Second messenger NAADP shows fast, dose-related impact on satiety cycle
4. The first impact factor for PLoS Biology ?13.9
5. Open Access journals get impressive impact factors
6. OHSU research shows vitamin C counteracts some negative impacts of smoking on unborn babies
7. York scientists warn of dramatic impact of climate change on Africa
8. Breath of the dragon: ERS-2 and Envisat reveal impact of economic growth on Chinas air quality
9. Amazon trees much older than assumed, raising questions on global climate impact of region
10. Health of Acehnese reefs in the wake of the tsunami shows human impacts more harmful
11. Infused spleen cells found not to impact islet recovery and reversal of type 1 diabetes in mice
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
Breaking Biology Technology: